Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Retained Earnings: 2012-2024

Historic Retained Earnings for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to -$3.6 billion.

  • Ptc Therapeutics' Retained Earnings rose 20.99% to -$2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 billion, marking a year-over-year increase of 20.99%. This contributed to the annual value of -$3.6 billion for FY2024, which is 11.06% down from last year.
  • Per Ptc Therapeutics' latest filing, its Retained Earnings stood at -$3.6 billion for FY2024, which was down 11.06% from -$3.3 billion recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Retained Earnings ranged from a high of -$1.6 billion in FY2020 and a low of -$3.6 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$3.3 billion (2023), whereas its average is -$3.2 billion.
  • Data for Ptc Therapeutics' Retained Earnings shows a maximum YoY tumbled of 36.82% (in 2020) over the last 5 years.
  • Ptc Therapeutics' Retained Earnings (Yearly) stood at -$1.6 billion in 2020, then declined by 28.80% to -$2.1 billion in 2021, then declined by 26.65% to -$2.7 billion in 2022, then decreased by 23.58% to -$3.3 billion in 2023, then fell by 11.06% to -$3.6 billion in 2024.